Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
2.
Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
3.
Department of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
4.
Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
Funds:
This work was supported by the National Institutes of Health (NIH) grants R01 CA112029 and R01 CA121211 and a Susan G Komen Foundation grant BCTR0707731 (to R.Z.).
The p53 tumor suppressor is a key transcription factor regulating cellular pathways such as DNA repair, cell cycle, apoptosis, angiogenesis, and senescence. It acts as an important defense mechanism against cancer onset and progression, and is negatively regulated by interaction with the oncoprotein MDM2. In human cancers, the TP53 gene is frequently mutated or deleted, or the wild-type p53 function is inhibited by high levels of MDM2, leading to downregulation of tumor suppressive p53 pathways. Thus, the inhibition of MDM2-p53 interaction presents an appealing therapeutic strategy for the treatment of cancer. However, recent studies have revealed the MDM2-p53 interaction to be more complex involving multiple levels of regulation by numerous cellular proteins and epigenetic mechanisms, making it imperative to reexamine this intricate interplay from a holistic viewpoint. This review aims to highlight the multifaceted network of molecules regulating the MDM2-p53 axis to better un-derstand the pathway and exploit it for anticancer therapy.
Paolino G, Podo Brunetti A, De Rosa C, et al. Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma. Melanoma Res, 2024, 34(6): 487-496.
DOI:10.1097/CMR.0000000000001003
2.
Illa SK, Mumtaz S, Nath S, et al. Characterization of runs of Homozygosity revealed genomic inbreeding and patterns of selection in indigenous sahiwal cattle. J Appl Genet, 2024, 65(1): 167-180.
DOI:10.1007/s13353-023-00816-1
3.
Ugonabo O, Mohamed M, Ezeh E, et al. A Rare Metastatic Primary Rectal Melanoma in a Geriatric Male. J Med Cases, 2022, 13(8): 369-373.
DOI:10.14740/jmc3929
4.
Si M, Cao X. Considering Computational Mathematics IGHG3 as Malignant Melanoma Is Associated with Immune Infiltration of Malignant Melanoma. Biomed Res Int, 2022, 2022: 4168937.
DOI:10.1155/2022/4168937
5.
Nonaka K, Kudou K, Sasaki S, et al. Primary anorectal malignant melanoma with laparoscopic abdominoperineal resection: a case study and review of the relevant literature. Int Cancer Conf J, 2020, 9(3): 116-122.
DOI:10.1007/s13691-020-00401-x
6.
Heo JR, Hwang KA, Kim SU, et al. A Potential Therapy Using Engineered Stem Cells Prevented Malignant Melanoma in Cellular and Xenograft Mouse Models. Cancer Res Treat, 2019, 51(2): 797-811.
DOI:10.4143/crt.2018.364